List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Medical Simulation Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the medical simulation market include continuous technological advancements, increasing concerns over patient safety, and increasing demand for minimally invasive treatments.
The requirement of medical simulation in minimally invasive surgery has been established over the past few years. The minimally invasive techniques are becoming the standards of surgical techniques, at a very fast pace, for a number of surgical procedures. These MIS procedures involve smaller incisions leading to quicker recovery, which helps in the growth of the overall market.
The use of medical simulation devices, along with standardized patient simulators, has gained rapid growth over the last few years, mainly due to increasing technological advancements and their adoption in the field of healthcare. The barriers to adopting simulation products and services in hospitals include lack of funding, less time for simulation exercises, release from job environment, lack of management interest, etc.
The METIman simulator is found to be one of the most advanced and realistic simulators in the recent times, developed by the CAE simulators. Thus, the rise in various technological advancements in the field of medical simulation is increasing the applications in healthcare to train healthcare professionals, and as a result of which, the growth of the market studied is expected to propel over the forecast period.
Scope of the Report
As per the scope of the report, medical simulation is the modern day methodology for training healthcare professionals through the use of advanced educational technology. Medical simulation is experiential learning that every healthcare professional may need, but cannot be always engaged in during real-life patient care. The market of medical stimulation is growing with increasing healthcare facilities.
Key Market Trends
Laparoscopic Surgical Simulators is the Segment under Interventional/Surgical Simulators that is Expected to Grow the Fastest during the Forecast Period
Surgeons are found shifting to MIS, primarily laparoscopy and robotic surgery from open surgery. However, the MIS, primarily laparoscopy and robotic surgery, requires skilled surgeons to deliver successful procedures. There has been a rapid adoption of the MIS in the cholecystectomy, appendectomy, gastric bypass, ventral hernia repair, colectomy, prostatectomy,tubal ligation, hysterectomy, and myomectomy procedures. Thus, the increasing MIS surgeries and the need for skilled professionals have propelled the laparoscopic surgical simulators market.
There are also cardiac surgeries that have been a major challenge for surgeons because of the complex nature of the surgery and the need for highly skilled professionals. Also, there has been a change observed in general surgery training, with the shift from open surgery toward the endovascular and minimally invasive approaches to disease management. Therefore, further simulation is expected to reduce the risks associated with the complex operations of cardiothoracic surgery and help create a more efficient, thorough, and uniform curriculum for cardiothoracic surgery fellowships.
Asia-Pacific Registered the Fastest Growth and is Expected to follow the Same Trend over the Forecast Period
Asia-Pacific is projected to exhibit the fastest growth, due to the increasing demand for healthcare simulation and its related services. The emerging economies of India and China are expected to majorly boost the market, due to the growing thrust on medical studies and research. In addition, the ease of doing business in Asian countries is high, due to the availability of high labor and low manufacturing cost. This is an important factor that is estimated to augment the market in Asia-Pacific.
Competitive Landscape
The market is highly fragmented with many players. With many small and medium players, the competition is high. The market has been experiencing the entry of new players over the last few years, owing to the rising popularity of simulation technology. The existing players are differentiating on the basis of price, quality, and technology.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Continuous Technological Advancements
4.2.2 Increasing Concerns over Patient Safety
4.2.3 Increasing Demand for Minimally Invasive Treatments
4.3 Market Restraints
4.3.1 High Cost of Simulators
4.3.2 Reluctance to Adopt New Training Methods
4.3.3 Limited Availability of Funds, Especially in the Developing and Underdeveloped Countries
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Products and Services
5.1.1 Products
5.1.1.1 Interventional/Surgical Simulators
5.1.1.1.1 Laparoscopic Surgical Simulators
5.1.1.1.2 Gynecology Surgical Simulators
5.1.1.1.3 Cardiac Surgical Simulators
5.1.1.1.4 Arthroscopic Surgical Simulators
5.1.1.1.5 Other Products
5.1.1.2 Task Trainers
5.1.1.3 Other Products and Services
5.1.2 Services and Software
5.1.2.1 Web-based Simulation
5.1.2.2 Medical Simulation Software
5.1.2.3 Simulation Training Services
5.1.2.4 Other Services and Software
5.2 By Technology
5.2.1 High-fidelity Simulators
5.2.2 Medium-fidelity Simulators
5.2.3 Low-fidelity Simulators
5.3 By End User
5.3.1 Academic and Research Institutes
5.3.2 Hospitals
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3D Systems
6.1.2 Canadian Aviation Electronics (CAE)
6.1.3 Gaumard Scientific Company Inc.
6.1.4 Kyoto Kagaku Co. Ltd
6.1.5 Laerdal Medical
6.1.6 Limbs & Things Ltd
6.1.7 Mentice AB
6.1.8 Simulab Corporation
6.1.9 Simulaids Inc.
6.1.10 Nasco
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Products and Services
Products
Interventional/Surgical Simulators
Laparoscopic Surgical Simulators
Gynecology Surgical Simulators
Cardiac Surgical Simulators
Arthroscopic Surgical Simulators
Other Products
Task Trainers
Other Products and Services
Services and Software
Web-based Simulation
Medical Simulation Software
Simulation Training Services
Other Services and Software
By Technology
High-fidelity Simulators
Medium-fidelity Simulators
Low-fidelity Simulators
By End User
Academic and Research Institutes
Hospitals
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Advanced Drug Delivery Systems Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 07-06-2019
Market Overview
The global advanced drug delivery systems market is expected to register a CAGR of 5% during the forecast period, 2019 to 2024. The factors that are driving this market include the development of new drugs and biologics, advancements in understanding human biology and diseases, and increased R&D spending.
The advanced drug delivery systems are more focused on the maintenance of bioavailability of drug as per patient requirement, as well as the rate of drug delivery. Genetic engineering led to the development of new strategies to deliver biotechnologically-derived protein, peptide drugs, and chemoimmunoconjugates. The advanced drugs and biologics have higher efficiency with a smaller dosage of the drug, and hence they have to be supported with advanced drug delivery systems to gain maximum efficacy from the drug. In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and reduction in drug dosage (hence lesser need for frequent dosing). The advanced sustained release systems help target intestinal infections and others.
The increasing disease burden across the world, the proven efficacy of controlled-release drug delivery systems in addressing a wide range of diseases, and the growing R&D trends by both the innovators and the generic players for advanced drug delivery systems, are propelling the growth of the market.
Scope of the Report
The concept of advanced drug delivery system is to increase the efficacy of drugs. Advanced drug delivery systems are adopted to increase the bioavailability of the drug, reduce adverse effects and side effects, and increase drug stability.
Key Market Trends
Oral Drug Delivery System Segment by Type to Hold the Highest CAGR
The oral drug delivery system segment of the global advanced drug delivery systems market is expected to record the highest CAGR over the forecast period.
Over the past decade, the oral controlled-release drug delivery system has received extensive attention, due to its flexibility, reduced dosing frequency, and better patient compliance. The aforementioned factor, in combination with a reasonable cost of oral controlled-release drug delivery system, has led to the ease of market penetration.
North America Dominates the Market and is Believed to Follow the Same Trend Over the Forecast Period
North America currently dominates the advanced drug delivery systems market and is expected to continue its stronghold for a few more years. The United States holds the largest share of this market in the North America region. Advancements in pharmacology and the increasing adoption of a novel drug delivery system are expected to drive the US drug delivery systems market during the forecast period.
Competitive Landscape
The advanced drug delivery systems market is moderately competitive. Some of the major players in this market are Boston Scientific Corporation, Baxter International, 3M, Abbott Laboratories, and GlaxoSmithKline PLC. Owing to the continuous technological advancements in the drug delivery system, there is a possibility of new entrants in the market in the coming future.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Development of New Drugs and Biologics
4.2.2 Advancements in Understanding Human Biology and Diseases
4.2.3 Increased R&D Spending
4.3 Market Restraints
4.3.1 Product Recalls of Advanced Drug Delivery Products
4.3.2 Challenges in Nanomedicine-based Drug Delivery
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Oral Drug Delivery System
5.1.2 Injection-based Drug Delivery System
5.1.3 Inhalation/Pulmonary Drug Delivery System
5.1.4 Transdermal Drug Delivery System
5.1.5 Trans mucosal Drug Delivery System
5.1.6 Carrier-based Drug Delivery System
5.1.7 Other Types
5.2 By Application
5.2.1 Cardiovascular Diseases
5.2.2 Oncology
5.2.3 Urology
5.2.4 Diabetes
5.2.5 CNS
5.2.6 Ophthalmology
5.2.7 Inflammatory Diseases
5.2.8 Infections
5.2.9 Other Applications
5.3 By Technology
5.3.1 Prodrug
5.3.2 Implants And Intrauterine Devices
5.3.3 Targeted Drug Delivery
5.3.4 Polymeric Drug Delivery
5.3.5 Other Technologies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3M
6.1.2 Abbott Laboratories
6.1.3 Amgen Inc.
6.1.4 Astrazeneca
6.1.5 Baxter International
6.1.6 Bayer Healthcare
6.1.7 Boston Scientific Corporation
6.1.8 Glaxosmithkline PLC
6.1.9 Merck & Co.
6.1.10 Novartis AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Oral Drug Delivery System
Injection-based Drug Delivery System
Inhalation/Pulmonary Drug Delivery System
Transdermal Drug Delivery System
Trans mucosal Drug Delivery System
Carrier-based Drug Delivery System
Other Types
By Application
Cardiovascular Diseases
Oncology
Urology
Diabetes
CNS
Ophthalmology
Inflammatory Diseases
Infections
Other Applications
By Technology
Prodrug
Implants And Intrauterine Devices
Targeted Drug Delivery
Polymeric Drug Delivery
Other Technologies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Medical Marijuana Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The major factors for the growth of the medical marijuana market include the increasing number of countries legalizing the use of medical marijuana, trend of producing edible products with cannabis, and favorable reimbursement environment and government support in selected countries, which are expected to experience a boost over the forecast period.
Each year, the legal use of cannabis for medical and recreational purposes is steadily growing, but it varies across countries, based on the possession, distribution, cultivation, and medical indications for its consumption. Therefore, over the forecast period, the change is expected to be slow, but more legal consumption of cannabis is expected in the developed market, which is expected to largely drive the market studied.
Currently, there is also an increasing use of marijuana as a functional food, with purported health benefits far outnumbering what consumers can get from kale, turmeric, or kombucha. With the new generation growing up in the United States, where cannabis is legal, new products are found rapidly entering the market, which is expected to grow rapidly over the forecast period. The growth of the market is also attributed to factors, like the trends of producing edible products with cannabis in selected countries. Therefore marijuana is expected to be included in the 2018 food trends, as the drug and its ingredients have been gradually making their way into the public market.
Doctors also prescribe medical marijuana to treat muscle spasms caused by multiple sclerosis, nausea, poor appetite, and weight loss, caused by chronic illness, such as HIV, nerve pain, and Crohn’s disease. Thus, with the increasing applications, there is a huge opportunity for marijuana for medicinal purposes as well.
Scope of the Report
As per the scope of the report, medical marijuana refers to the whole, unprocessed marijuana plant, or its basic extracts, for the treatment of several diseases and other related symptoms. Scientific studies show that chemical cannabinoids could help treat a range of diseases and symptoms, which has attracted several biopharmaceutical companies, globally, over the past two decades. The market is expected to witness significant growth, owing to legalization in several countries and high demand for both medical and recreational purposes.
Key Market Trends
Chronic Pain is the Segment under Application that is Expected to Experience the Fastest Growth during the Forecast Period
There are many studies that have shown that medical cannabis is found to be an effective method for the treatment of chronic pain, and that it is far safer than many other options. It is an affordable, natural alternative that lacks side effects and is traditionally used to treat chronic pain. There are also several ongoing researches on medical marijuana for the treatment of chronic pain, which is expected to directly impact the growth of the market.
Marijuana is also being used for the treatment of arthritis, as it has the potential to reduce inflammation, as well reduce pain. There is also an increasing research on medical marijuana for the treatment of cancer and commercially available cannabinoids, which are approved drugs for chemotherapy, and which are likely to augment the growth of the market. Marijuana, being an effective treatment for neuropathic pain, is expected to further rise over the forecast timeframe.
North America Accounted for the Largest Share in the Global Market
North America holds the major share in the medical marijuana market, and is expected to show a similar trend over the forecast period, without significant fluctuations. The surging pace of cannabis legalization in the United States is one of the key factors contributing to its increased demand. There are also many marijuana programs in the United States that have accelerated, and most of the states have started to approach medical marijuana from the perspective of good public health.
Competitive Landscape
The market studied is dominated by a few major players, and currently, only in a few countries, the use of cannabis is legal. Because of this, several companies were not able to launch their products.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Countries Legalizing the Use of Medical Marijuana
4.2.2 Trend of Producing Edible Products with Cannabis
4.2.3 Favorable Reimbursement Environment and Government Support in Certain Countries
4.3 Market Restraints
4.3.1 Lack of Awareness about the Dosage and Medicinal Properties of Marijuana
4.3.2 Social Stigma Related to Cannabis Use
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Chronic Pain
5.1.2 Arthritis
5.1.3 Migraine
5.1.4 Cancer
5.1.5 Other Applications
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Canopy Growth
6.1.2 Lexaria Corp.
6.1.3 United Cannabis Corporation
6.1.4 Aurora Cannabis
6.1.5 Cannabis Sativa Inc.
6.1.6 Cara Therapeutics Inc.
6.1.7 GW Pharmaceuticals PLC
6.1.8 LivWell Enlightened Health LLC
6.1.9 Aphria Inc
6.1.10 Medical Marijuana Inc.
6.1.11 Lexaria Corporation
6.1.12 United Cannabis Corporation
6.1.13 Aurora Cannabis
6.1.14 Cannabis Sativa Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Application
Chronic Pain
Arthritis
Migraine
Cancer
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Infant Nutrition Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global infant nutrition market was valued at USD 71.40 billion in 2018 and is estimated to reach USD 98.90 billion in 2024, witnessing a CAGR of 5.58%. There are certain factors propelling the growth of the market, which include the increase in working mother population, higher spending on baby health, and the rising demand for organic baby food.
At present, parents are found spending more on their babies compared to the previous years, owing to several social factors. Presently, children are deemed more worthy of protection than they used to be. According to a number of surveys, parents spend a high amount of money on their babies, sometimes out of guilt, out of shame, or out of social anxiety.
Over the recent years, there has been a remarkable rise that has been observed in the number of young working mothers. This has worked as a key factor in propelling the growth of the infant food nutrition market, as these working mothers are majorly dependent on processed infant nutrition products. Therefore, organic food has been observed to be one of the fastest-growing sectors in the food industry overall, experiencing double-digit growth in most developed markets, compared with a single-digit growth rate for conventional food products. The global demand is increasing, owing to factors, such as the desire of parents to feed their babies healthier foods.
In addition, factors, such as the growth of the middle class, rapid urbanization, and rising rates of female participation in the labor force in many developing markets have encouraged the adoption of convenience-oriented lifestyles, further making prepared baby foods and baby formula more desirable. The increasing middle-class population in the emerging and developing countries has opened new horizons in the infant nutrition market, owing to the fact that the need for products, compatible with a working mom’s schedule, is growing.
In the next few years, it is expected that the global infant nutrition market will show healthy growth. In the last few years, the sale of infant nutrition products in developed countries has shown a single-digit growth rate.
Scope of the Report
Infant nutrition is a substitute food for breast milk. The initial six months after birth plays a very crucial role in the development of a child, wherein ensuring optimal nutrition during this period is of paramount importance. Breast milk is highly nutritious and contains carbohydrates, proteins, fats, minerals, and vitamins imperative for the development of the child. However, in certain cases, the mother may not be able to produce breast milk or may not be able to breastfeed the baby due to other reasons. In such cases, infant nutrition products act as a suitable substitute.
Key Market Trends
Prepared Food is Expected to hold its Highest Market Share in the Baby Food Segment
In the product type segmentation of the infant nutrition market, the prepared food sub-segment under the baby food segment is believed to have the largest market size and is expected to witness a CAGR of 6.51% during the forecast period.
The market size of the baby food segment can be attributed to the current busy lifestyle of people and the emergence of a variety of organic and healthy food for infants. The extensive sale of prepared food is mainly attributed to its ease of access. As the manufacturers of prepared food, most companies are now coming up with more organic food products, which is free from preservatives and residues of fertilizers and pesticides. However, there are also some parents who prefer to prepare the baby’s food by themselves, so as to be assured of hygiene and nutrition.
Therefore there is also a demand for the dried food that is on a rise, majorly due to the increasing trust of parents upon the quality of food, which is provided by the companies and increasing improvisation that is continuously being done in the food products by the manufacturers. There are other baby foods segment of the market majorly inclusive of the juices and products that are rich in omega-3 DHA and arachidonic acid (ARA), along with other nutritional products.
North America is expected to witness the highest CAGR throughout the forecast period
The presence of high per capita healthcare expenditure, coupled with high awareness levels and rising disposable income, is contributing to the growth of the market in the region. The average age at which American women are giving birth has been rising as young women are increasingly prioritizing their careers over family planning. Hence, a rise in parental concerns, with respect to baby’s health and nutrition, is driving the growth of the North American regional market. There are also consumers, especially in the developed countries, who are willing to pay for premium amounts for such products, owing to the general perception of these products being more healthy and safe as compared to conventional products.
Competitive Landscape
There are stringent regulatory scenarios that create high entry barriers for new entrants in the market. As per the data of the China Certification and Accreditation Administration (CNCA), after implementation of quality and safety standards in 2013, out of over 800 foreign brands selling their product of infant formula, only 94 have received approval to sell their products in China, while only two-thirds of the local Chinese manufacturers have received production permit renewals.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Working Mothers Population
4.2.2 Higher Spending on Baby Health
4.2.3 Rising Demand for Organic Baby Food
4.3 Market Restraints
4.3.1 Concerns Regarding Food Safety
4.3.2 Stringent Regulation for Infant Food
4.4 Industry Attractiveness Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Infant Formula
5.1.1.1 First Infant Formula
5.1.1.2 Follow-on Formula
5.1.1.3 Growing-up Formula
5.1.1.4 Specialty Baby Formula
5.1.2 By Baby Food
5.1.2.1 Prepared Food
5.1.2.2 Dried Food
5.1.2.3 Other Baby Foods
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Baby Gourmet Foods Inc.
6.1.3 Bellamy’s Australia Limited
6.1.4 Danone S.A.
6.1.5 FrieslandCampina
6.1.6 Reckitt Benckiser (Mead Johnson)
6.1.7 Nestlé S.A.
6.1.8 Perrigo Company Plc
6.1.9 Parent’s Choice Infant Formula
6.1.10 The Kraft Heinz Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
By Infant Formula
First Infant Formula
Follow-on Formula
Growing-up Formula
Specialty Baby Formula
By Baby Food
Prepared Food
Dried Food
Other Baby Foods
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Influenza Diagnostics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global influenza diagnostics market was valued at USD 492.42 million in 2018, and is estimated to be valued at USD 731.97 million in 2024, witnessing a CAGR of 6.83%. Certain factors that are driving the market growth include increasing prevalence of influenza and related chronic diseases, growth in research funding for influenza diagnostics, and rising demand for early diagnosis and control of influenza.
Influenza is recognized as a crucial cause of morbidity and mortality in the human population, which is leading to the development and use of diagnostics that are intended for reducing consequent health and economic impacts. According to WHO, in 2018, influenza caused severe sickness or death mainly in patients at a high risk and illness range from mild to severe and even death. Also, this annual increase is projected to result in about 3-5 million cases of severe illness, and about 290,000-650,000 deaths, globally.
Various initiatives and research funding are bolstering the growth of the market. For instance, National Institute of Allergy and Infectious Disease (NIAID) has supported a broad portfolio of the influenza research, which includes studies that are informing the development of vaccines, diagnostics, and therapeutics against seasonal and pandemic influenza. Similarly, in 2018, a non-profit association between academic, government, and industry medical researchers, called Human Vaccine Project, launched the Universal Influenza Vaccine Initiative. Thus, growth in research funding by the government and companies for influenza diagnostics is driving the market.
However, it is critical to ensure that all the rapid antigen flu tests meet new FDA requirements for approval. Hence, the stringent FDA regulations act as significant restraints for the market.
Scope of the Report
Influenza, also known as flu, is a highly contagious infectious disease caused by a virus. This is an infection of the respiratory passages, which causes fever and severe aches. The influenza diagnostic market includes the tests that are conducted for the diagnosis of influenza cases. As per the scope of this report, only the test kits and reagents that are being used for the diagnosis of influenza have been taken into account for the calculation of the total market size.
Key Market Trends
Rapid Influenza Diagnostic Test (RIDT) is Expected to hold its Highest Market Share in the Test Type Segment
In the test type segment of the influenza diagnostics market, among all traditional diagnostic tests, the rapid influenza diagnostic test (RIDT) is believed to have the largest market size and is expected to witness a CAGR of 6.87% during the forecast period.
Rapid influenza diagnostic tests (RIDTs) are immunoassays, which help to identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and qualitatively provide the results. It can diagnose patients, who are present with influenza-like illness, mainly if it is performed within the first four days of the onset of symptoms.
The rising popularity of RIDT is due to the benefits of faster result and simple usage. Some of the RIDTs are also approved for office/bedside use as well. The RIDT segment is also expected to witness rapid growth, as a result of their common usage in point-of-care settings.
However, one of the major drawback associated with RIDT is that it gives false negative results, due to its low to moderate sensitivities (50-70%). Healthcare policymakers began to recognize the impact of its low sensitivity in 2009, when the novel H1N1 influenza epidemic occurred.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for influenza diagnostics and is expected to continue its stronghold for a few more years.
As per data published by the Centers for Disease Control and Prevention (CDC), RIDTs are commonly available across the region. The reason behind the wide availability of the test is the reduced time span needed to generate results. RIDT can yield results in 15 minutes. With increasing influenza-associated hospitalization and pediatric deaths and the interest of government organizations to better manage the disease, the North American influenza diagnostics market is expected to grow in the future.
Competitive Landscape
The influenza diagnostics market is highly competitive and consists of a few major players. In terms of market share, few of the major players currently dominate the market. Companies, like Coris BioConcept, DiaSorin SpA, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Quidel Corporation, and Sekisui Diagnostics., among others, hold the substantial share in the market.
Various developments have recently been taking place in the market; for instance, in March 2018, Sekisui Diagnostics launched the Silaris Influenza A and B test, developed in collaboration with Mesa Biotech. Also, in October 2017, Abbott Laboratories acquired Alere Inc. (Alere), a diagnostic device and service provider, which strengthened the company’s diagnostics presence.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Influenza and Related Chronic Diseases
4.2.2 Growth in Research Funding for Influenza Diagnostics
4.2.3 Rising Demand for Early Diagnosis and Control of Influenza
4.3 Market Restraints
4.3.1 Product Safety and High Cost of Development
4.3.2 Stringent Government Regulations
4.3.3 Variability in Sensitivity and Specificity among Influenza Diagnostic Tests
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Test Type
5.1.1 Traditional Diagnostic Test
5.1.1.1 Rapid Influenza Diagnostic Test (RIDT)
5.1.1.2 Viral Culture
5.1.1.3 Direct Fluorescent Antibody (DFA) Test
5.1.1.4 Serological Assay
5.1.2 Molecular Diagnostic Assay
5.1.2.1 RT-PCR
5.1.2.2 Nucleic Acid Sequence-based Amplification (NASBA) Test
5.1.2.3 Loop-mediated Isothermal Amplification-based Assay (LAMP)
5.1.2.4 Simple Amplification-based Assay (SAMBA)
5.1.2.5 Other Molecular Diagnostic Assays
5.2 End User
5.2.1 Hospital
5.2.2 Research Laboratory
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Becton, Dickinson and Company
6.1.3 Coris BioConcept
6.1.4 DiaSorin SpA
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Luminex Corporation
6.1.7 Meridian Bioscience Inc.
6.1.8 Quidel Corporation
6.1.9 Sekisui Diagnostics
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Test Type
Traditional Diagnostic Test
Rapid Influenza Diagnostic Test (RIDT)
Viral Culture
Direct Fluorescent Antibody (DFA) Test
Serological Assay
Molecular Diagnostic Assay
RT-PCR
Nucleic Acid Sequence-based Amplification (NASBA) Test
Loop-mediated Isothermal Amplification-based Assay (LAMP)
Simple Amplification-based Assay (SAMBA)
Other Molecular Diagnostic Assays
End User
Hospital
Research Laboratory
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
HIV DRUGS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 102 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 102 pages
- Published: 04-08-2019
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV virus, thereby reducing the risk of its transmission. According to the latest report by IMARC Group, titled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the global HIV drugs market exceeded a value of US$ 24.7 Billion in 2018.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, the market value is projected to reach US$ 22.5 Billion by 2024, declining at a CAGR of 2.5% during 2019-2024.
Market Summary:
Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors – CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report:
- How has the global HIV drugs market performed so far and how will it perform in the coming years?
- What are the key regions in the global HIV drugs market?
- Which are the popular class types in the global HIV drugs market?
- What are the major distribution channels in the global HIV drugs market?
- What are the various stages in the value chain of the global HIV drugs market?
- What are the key driving factors and challenges in the global HIV drugs market?
- What is the structure of the global HIV drugs market and who are the key players?
- What is the degree of competition in the global HIV drugs market?
- How are HIV drugs manufactured?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global HIV Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Price Analysis 5.4 Market Breakup by Drug Class 5.5 Market Breakup by Distribution Channel 5.6 Market Breakup by Region 5.7 Market Forecast 5.8 SWOT Analysis 5.8.1 Overview 5.8.2 Strengths 5.8.3 Weaknesses 5.8.4 Opportunities 5.8.5 Threats 5.9 Value Chain Analysis 5.9.1 Overview 5.9.2 Research and Development 5.9.3 Raw Material Procurement 5.9.4 Manufacturing 5.9.5 Marketing 5.9.6 Distribution 5.9.7 End-Use 5.10 Porters Five Forces Analysis 5.10.1 Overview 5.10.2 Bargaining Power of Buyers 5.10.3 Bargaining Power of Suppliers 5.10.4 Degree of Competition 5.10.5 Threat of New Entrants 5.10.6 Threat of Substitutes 6 Market Breakup by Drug Class 6.1 Nucleoside Reverse Transcriptase Inhibitors 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Multi-Class Combination Products 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Protease Inhibitors 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 HIV Integrase Strand Transfer Inhibitors 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Fusion Inhibitors and Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Distribution Channel 7.1 Hospital Pharmacies 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Retail Pharmacies 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Online Pharmacies 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Europe 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Asia Pacific 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Middle East and Africa 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Latin America 8.5.1 Market Trends 8.5.2 Market Forecast 9 HIV Drugs Manufacturing Process 9.1 Product Overview 9.2 Raw Material Requirements 9.3 Manufacturing Process 9.4 Key Success and Risk Factors 10 Competitive Landscape 10.1 Market Structure 10.2 Market Breakup by Key Players 10.3 Profiles of Key Players 10.3.1 Boehringer Ingelheim International GmbH 10.3.2 Merck & Co., Inc. 10.3.3 ViiV Healthcare 10.3.4 AbbVie 10.3.5 F. Hoffmann-La Roche Ltd. 10.3.6 Teva Pharmaceutical Industries Ltd. 10.3.7 Bristol-Myers Squibb 10.3.8 Gilead Sciences, Inc. 10.3.9 Johnson & Johnson 10.3.10 Cipla Limited 10.3.11 Daiichi Sankyo 10.3.12 Emcure 10.3.13 Hetero Drugs 10.3.14 Mylan |
Market Breakup by Drug Class
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Products
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors — CCR5 Co-Receptor Antagonist
- Fusion Inhibitors and Others
- Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America